INTRODUCTION AND OBJECTIVES:
A field of cancer susceptibility exists for many tumors, including prostate. Here we question whether digital imaging and computer-based analysis can distinguish differences in benign appearing prostate biopsy tissues from men with and without cancer.
METHODS: Using an initial training set of 59 patients and a subsequent blinded validation set (116 subjects), we digitally imaged H&E biopsy slides utilizing the VectraTM platform. InForm2.1.1 software quantitatively measured features of epithelial and stroma. Non-tumor associated (NTA) cases underwent !2 previous negative biopsies and tumor associated (TA) cases all underwent radical prostatectomy. Additional imaging features were analyzed using custom Matlab software. Epithelial cell number was evaluated using immunohistochemistry.
RESULTS: Epithelial to stromal area ratio is greater in TA CONCLUSIONS: This study is the first to report an increase in the epithelial to stromal area and other alterations detectable with computer-based imaging analysis in histologically benign prostate biopsies from men with prostate cancer. These changes may be useful in determining cancer presence. We investigated the potential impact of CAD system on the detection rate of PCa in a series of FPB performed in two different centres.
METHODS: From March 2016 to October 2018, data on FPB were collected from prospective data set at two different centres. We compared PCa detection rate with a per patient and per target area analysis, in two groups of FPB performed either with the assistance of CAD system or using MRI only.
Chi Square and Student t test were used to compare categorical and continuous variables, respectively.
RESULTS: A total of 183 FPB were performed transperineally with Biopsee Fusion System, 89 with the assistance of CAD System (Watson Elementary). The two cohorts were homogeneous for age, baseline PSA, prostate volume, number of target areas and number of target cores, while the CAD assisted group had a significantly higher number of total cores (p<0.001). (Table 1) On a patient based analysis the overall detection rate of any PCa and clinically significant (cs) PCa were 56.3% and 30.6%, respectively. The same outcomes were comparable between the CAD assisted and MRI only FPB groups (59.6% vs 53.2% [p[0.45] and 30.3% vs 30.9%, [p[0.99] ) for any prostate cancer and csPca, respectively.
On a target area based analysis, the overall detection rate of any PCa was 54.1%, with non-significant differences between groups (51.5 vs 48.5, for the CAD assisted and MRI only FPB, respectively e1180 THE JOURNAL OF UROLOGY Ò Vol. 201, No. 4S, Supplement, Monday, May 6, 2019 
